An overview of the DNA damage response in female reproductive system and breast cancers: A narrative review
International Journal of Reproductive BioMedicine (IJRM) · 18.08.2026 · 24 (6)
DOI: 10.18502/ijrm.v24i6.21457 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Reproductive BioMedicine (IJRM), online erschienen am 18.08.2026. Verfasst von Mandana Zafari und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Midwifery, Sar.C., Islamic Azad University, Sari, Iran. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The DNA damage response (DDR) is a fundamental cellular network that preserves genomic integrity, and its dysregulation drives initiation, progression, and therapeutic response in female reproductive system and breast cancers. This narrative review provides a comparative analysis of DDR alterations across ovarian, endometrial, cervical, and breast cancers, synthesizing molecular studies, clinical trials, and international guidelines from PubMed/MEDLINE, Scopus, and Web of Science. DDR alterations vary substantially among these cancers, reflecting differences in tissue origin, hormonal regulation, and viral oncogenesis. Homologous recombination repair defects, particularly in breast cancer susceptibility 1/2, partner and localizer of BRCA2, ataxia telangiectasia mutated, and checkpoint kinase 2), are prevalent in ovarian, endometrial, and breast cancers, predicting sensitivity to platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitors. In endometrial cancer, homologous recombination deficiency predominates in high-grade tumor protein p53-mutated subtypes, while Fanconi anemia pathway alterations characterize aggressive serous carcinomas. Cervical cancer exhibits virus-induced DDR disruption and replication stress. Quantitative biomarkers, including tumor mutational burden, microsatellite instability, Radiation sensitive 51, Fanconi anemia complementation group D2, excision repair cross-complementation group 1, and DDR-related microRNAs enable patient stratification. Emerging ataxia telangiectasia and Rad3-related and WEE1 inhibitors show promise in combination regimens. Understanding of tumor-specific DDR enables rational therapeutic stratification, providing a framework for precision oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Midwifery, Sar.C., Islamic Azad University, Sari, Iran.
- Health Reproductive Research Center, Sari Branch, Islamic Azad University, Sari, Iran.
- Department of Anatomical Sciences, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Anatomical Sciences, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
- Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran.
Zitieren
APA
Zafari, M., Zarei, H., Sadeghi, E., Lotfi Asrami, F., Bahmani, F., Jahani, S., Maliki, D. S. K., Musavi, H., & Abdollahi, A. (2026). An overview of the DNA damage response in female reproductive system and breast cancers: A narrative review. International Journal of Reproductive BioMedicine (IJRM), 24(6). https://doi.org/10.18502/ijrm.v24i6.21457
Vancouver
Zafari M, Zarei H, Sadeghi E, Lotfi Asrami F, Bahmani F, Jahani S, et al. An overview of the DNA damage response in female reproductive system and breast cancers: A narrative review. International Journal of Reproductive BioMedicine (IJRM). 2026;24(6). doi:10.18502/ijrm.v24i6.21457
BibTeX
@article{Zafari2026,
author = {Zafari, Mandana and Zarei, Hooman and Sadeghi, Elham and Lotfi Asrami, Fatemeh and Bahmani, Farima and Jahani, Saleheh and Maliki, Dhifaf Saleem Kareem and Musavi, Hadis and Abdollahi, Amirsaleh},
title = {An overview of the DNA damage response in female reproductive system and breast cancers: A narrative review},
journal = {International Journal of Reproductive BioMedicine (IJRM)},
year = {2026},
volume = {24},
number = {6},
doi = {10.18502/ijrm.v24i6.21457}
}
EUVIMED